When the prevalence of dyslipidemia was stratified by anti-dyslipidemia medication use and total cholesterol levels (>240 mg/dL), there was an increasing trend in the proportion of individuals receiving anti-dyslipidemia medication ( Fig. 3C and 3D ).
← all excerpts
Trends in Prevalence of Obesity and Related Cardiometabolic and Renal Complications in Korea: A Nationwide Study 2007 to 2022.
1
—
—